EverBank Financial Corp. EVER 深 滬
已收盤 12-12 16:00:00 美东时间
27.74
+0.060
+0.22%
華盛通- 最 高28.7299
- 今 開28.35
- 成交量 36.60万股
- 最 低 27.70
- 昨 收 27.68
- 總市值 10.13亿
- 52周最高 30.03
- 市盈率 靜 31.60
- 換手率 1.00%
- 52周最低 17.03
- 委 比 50.28%
- 總股本 3651.29万
- 歷史最高 63.44
- 量 比 0.95
- 振 幅 3.72%
- 歷史最低 4.05
- 每 手 1
- 風險率 2.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多JP Morgan Maintains Overweight on EverQuote, Raises Price Target to $32
JP Morgan analyst Cory Carpenter maintains EverQuote (NASDAQ:EVER) with a Overweight and raises the price target from $30 to $32.
12-13 03:05
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
JP Morgan Maintains Overweight on EverQuote, Raises Price Target to $30
JP Morgan analyst Cory Carpenter maintains EverQuote (NASDAQ:EVER) with a Overweight and raises the price target from $29 to $30.
11-04 23:03
电话会总结 ｜ EverQuote(EVER)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据EverQuote 2025年第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收达到1.739亿美元，同比增长20%，创季度新高 - 汽车保险营收1.576亿美元，同比增长超过21%，占总营收主要部分 - 房屋及租户保险营收1,630万美元，同比增长15% **盈利能力：** - 净利润1,890万美元，创历史新高，较去年同期的1,160万美元大幅增长 - 调整后EBITDA达到2,510万美元，同比增长33%，增幅显著超过营收增长率 - 调整后EBITDA利润率为14.4%，体现出运营杠杆效应和效
11-04 12:31
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
EverQuote Earnings Preview
EverQuote (NASDAQ:EVER) is gearing up to announce its quarterly earnings on Mon...
11-01 03:01
Evergold Corp. Secures Funding for DEM Gold Prospect Drilling
An update from Evergold Corp ( ($TSE:EVER) ) is now available. Evergold Corp. h...
10-29 19:48
Citius Oncology Announced It Has Finalized An Exclusive Agreement With EVERSANA To Support The Q4 2025 U.S. Commercialization Of LYMPHIR
EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapyCRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius
10-16 20:52
Evergold proposes ten for one share consolidation
Evergold (TSXV:EVER:CA) has intended to complete a consolidation of its outstanding common shares on the basis of ten (10) pre-consolidation shares for one (1) post-consolidation, in connection with t...
10-07 19:13
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
